Ticagrelor
Product Intro
Ticagrelor is a new antiplatelet agglutination drug, which was successfully developed by AstraZeneca. It is the first reversible binding oral P2Y12 adenosine diphosphate receptor antagonist in the world. It can reversibly act on purinoceptor2 (P2) subtype p2chemicalbooky12 on vascular smooth muscle cells (VSMC) without metabolic activation, It has obvious inhibitory effect on platelet aggregation caused by adenosine diphosphate (ADP), and takes effect rapidly after oral use, which can effectively improve the symptoms of patients with acute coronary heart disease. Unlike thiophenopyridine drugs, ticagrel is a reversible inhibitor of P2Y12 receptor, so it is especially suitable for patients who need to undergo surgery after early anticoagulant treatment.
Function
This product is used in patients with acute coronary syndrome (unstable angina pectoris, non ST segment elevation myocardial infarction or ST segment elevation myocardial infarction), including patients receiving drug treatment and percutaneous coronary intervention (PCI), to reduce the incidence of thrombotic cardiovascular events.
Application
It is used to reduce cardiovascular death and heart attack in patients with acute coronary syndrome (ACS).
Copyright © Shanghai Norky Pharmaceutical Co., Ltd. All Rights Reserved 沪ICP备20013299号 Powered by www.300.cn